Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 DAC 2mg Dosage Protocol | PeptideDosages.com

CJC-1295 DAC (2 mg Vial) Dosage Protocol CJC-1295 DAC Dosage Chart CJC-1295 DAC is dosed at 2 mg weekly via subcutaneous injection in educational protocols. A 2 mg vial reconstituted with bacteriostatic water yields about 2.0 mg/mL. This information is for res

CJC-1295 DAC (2 mg Vial) Dosage Protocol

CJC-1295 DAC Dosage Chart

CJC-1295 DAC is dosed at 2 mg weekly via subcutaneous injection in educational protocols. A 2 mg vial reconstituted with bacteriostatic water yields about 2.0 mg/mL. This information is for research and educational use only.

Reconstitute: Add 1.0 mL bacteriostatic water → 2.0 mg/mL (2,000 mcg/mL) concentration.

Typical weekly dose: 2,000 mcg (2 mg) once weekly — the full vial per injection.

Easy measuring: At 2.0 mg/mL, 1 unit = 0.01 mL = 20 mcg on a U-100 insulin syringe; full dose = 100 units (1.00 mL).

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

CJC-1295 DAC dosage protocols leverage this long-acting growth hormone-releasing hormone (GHRH) analog’s unique albumin-binding technology, which extends its half-life to approximately 6–8 days[1][2]. By stimulating pulsatile growth hormone (GH) release while preserving natural GH rhythms, CJC-1295 DAC can elevate GH levels 2–10 fold and IGF-1 levels 1.5–3 fold in human studies[3]. Benefits may include enhanced muscle growth and recovery, improved fat metabolism, better sleep quality, and anti-aging effects through sustained GH/IGF-1 axis activation[4][5]. This educational protocol presents a once-weekly subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read CJC-1295 DAC Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard Weekly Approach (1 mL = 2.0 mg/mL)

Weeks 1–12

2,000 mcg (2 mg)

100 units (1.00 mL)

Frequency: Inject once weekly subcutaneously, preferably in the evening before bed to align with natural nocturnal GH surges[6]. The peptide’s extended half-life (~6–8 days) supports weekly administration without significant loss of activity between doses[1].

Reconstitution Steps

Draw 1.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming or direct stream onto the powder.

Gently swirl/roll until dissolved (do not shake vigorously).

Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–12 week weekly protocol.

Peptide Vials (CJC-1295 DAC, 2 mg each):

8 weeks: 8 vials (1 vial/week)

12 weeks: 12 vials (1 vial/week)

Insulin Syringes (U-100, 1 mL capacity):

Per week: 1 syringe

8 weeks: 8 syringes

12 weeks: 12 syringes

Bacteriostatic Water (10 mL bottles): Use 1.0 mL per vial for reconstitution.

8 weeks (8 vials): 8 mL → 1 × 10 mL bottle

12 weeks (12 vials): 12 mL → 2 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each week.

Per week: 2 swabs

8 weeks: 16 swabs → recommend 1 × 100-count box

12 weeks: 24 swabs → recommend 1 × 100-count box

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing & Reconstitution Guide

Each peptide reconstituted in its own vial — CJC-1295 DAC dosed in mg, Ipamorelin in mcg
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Research Liquids

Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper

RESEARCH

CJC-1295 WITH DAC 2MG — Research Grade

C165H271N47O46S 3647.2 g/mol 863288-34-0 ES-CJCD-2 CJC-1295 with DAC incorporates a maleimidoproprionic acid (MPA) side chain enabling covalent binding to serum albumin in solution. This albumin-binding mechanism substantially extends the compound half-life in research models compared to unmodified GHRH or CJC-1295 No DAC. Used in research examining continuous versus pulsatile GHRH receptor stimulation protocols and differential downstream signalling outcomes associated with prolonged versus intermittent GHRHR activation in cell-based assay models. Its extended activity profile makes it a useful comparator in studies designed to distinguish acute from chronic receptor engagement effects. Element SARMs supplies CJC-1295 with DAC at 2mg per vial. USA-manufactured and verified at 99%+ purity by HPLC and Mass Spectrometry. Reconstitute with bacteriostatic water. Store at -20C. WARNING: For research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified research professionals only.